Jamal Leila, Robinson Jill O, Christensen Kurt D, Blumenthal-Barby Jennifer, Slashinski Melody J, Perry Denise Lautenbach, Vassy Jason L, Wycliff Julia, Green Robert C, McGuire Amy L
a Center for Medical Ethics and Health Policy, Baylor College of Medicine, and Johns Hopkins Berman Institute of Bioethics , Johns Hopkins University.
b Center for Medical Ethics and Health Policy , Baylor College of Medicine.
AJOB Empir Bioeth. 2017 Apr-Jun;8(2):82-88. doi: 10.1080/23294515.2017.1287786. Epub 2017 Jan 27.
Clinical genome and exome sequencing (CGES) is being used in an expanding range of clinical settings. Most approaches to offering patients choices about learning CGES results classify results according to expert definitions of clinical actionability. Little is known about how patients conceptualize different categories of CGES results.
The MedSeq Project is a randomized controlled trial studying the use of whole-genome sequencing (WGS) in primary care and cardiology. We surveyed 202 patient-participants about different kinds of WGS results and conducted qualitative interviews with 49 of these participants. Interview data were analyzed both inductively and deductively using thematic content analysis.
Participants demonstrated high levels of study understanding and genetic literacy. A small majority of participants wanted to learn all of their WGS results (n = 123, 61%). Qualitative data provided a deeper understanding of participants' perspectives about different types of WGS results. Participants did not have the same views about which WGS results would be actionable or upsetting to learn. They conceptualized variants of uncertain significance (VUS) in a variety of different ways. Many participants expressed optimism that the uncertainty associated with VUS results could be reduced over time.
Proposals to determine which WGS/CGES results to disclose by soliciting patient preferences may fail to appreciate the complex ways patients think about disease and the information WGS/CGES can produce. Our findings challenge prevailing methods of facilitating patient choice and assessing the benefits and harms related to the return of WGS/CGES results, which mostly rely on expert definitions of clinical utility to categorize the kinds of results patients can learn.
临床基因组和外显子组测序(CGES)正在越来越多的临床环境中得到应用。大多数让患者选择是否了解CGES结果的方法都是根据临床可操作性的专家定义对结果进行分类。对于患者如何理解不同类别的CGES结果,我们知之甚少。
MedSeq项目是一项随机对照试验,研究全基因组测序(WGS)在初级保健和心脏病学中的应用。我们对202名患者参与者进行了关于不同类型WGS结果的调查,并对其中49名参与者进行了定性访谈。访谈数据采用主题内容分析法进行归纳和演绎分析。
参与者对研究的理解和基因素养水平较高。一小部分多数参与者希望了解所有的WGS结果(n = 123,61%)。定性数据让我们更深入地了解了参与者对不同类型WGS结果的看法。对于哪些WGS结果具有可操作性或了解后会令人不安,参与者没有相同的看法。他们以多种不同方式对意义未明的变异(VUS)进行概念化。许多参与者表示乐观,认为随着时间的推移,与VUS结果相关的不确定性可能会降低。
通过征求患者偏好来确定披露哪些WGS/CGES结果的提议,可能没有认识到患者思考疾病以及WGS/CGES所能产生的信息的复杂方式。我们的研究结果对当前促进患者选择以及评估与WGS/CGES结果反馈相关的利弊的方法提出了挑战,这些方法大多依赖临床效用的专家定义来对患者可以了解的结果类型进行分类。